Date: 2018-06-26
Type of information: Nomination
Compound: senior partner
Company: Gurnet Point Capital (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 26, 2018, Gurnet Point Capital announced that Dr. Sophie Kornowski is to be appointed as Senior Partner. Dr. Kornowski currently serves as Executive Vice-President of Roche Partnering, where she focuses on establishing external partnerships with biotechnology and research institutions worldwide for Roche Holding AG, one of the world’s largest healthcare companies. She is also a member of Roche's Extended Global Executive Committee and will continue as a member of the Board of Directors of Chugai Pharmaceutical Co Ltd in Japan.
- Dr. Kornowski and her team completed over 50 deals per year in her current role as head of partnering at Roche. Previously, she led Roche's major affiliate for five years in France. Dr. Kornowski also spent 11 years in various leadership roles at Merck in the US, France and Israel. She spent the early years of her career at Abbott and Sanofi, in France and the US. Dr. Kornowski has an MBA from the University of Chicago Booth and a PhD in Pharmacy from Paris Descartes University.
- Following her departure from Roche, Dr. Kornowski initially will be based in Geneva (Switzerland) as an advisor to Ernesto Bertarelli’s Waypoint Capital group before taking up her position at Gurnet Point’s headquarters in Cambridge, Massachusetts later this year. Waypoint Capital advises the trusts and funds associated with the Bertarelli family, the principal investors in Gurnet Point Capital.
Financial terms:
Latest news:
Is general: Yes
